Tag: revenue

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Fortrea’s business, operations, and prospects, including allegations that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the transition services agreements; (iii) as a result, Fortrea’s previously announced EBITDA targets for 2025 were inflated; and (iv) accordingly, the viability of the Company’s post-Spin-Off business model, as well as its business and/or financial prospects, were overstated.

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

The Sleep Apnea Devices Market presents robust growth opportunities, especially in regions like North America and Europe where awareness, infrastructure, and reimbursement support are strong. However, high device costs and poor compliance rates remain critical hurdles. For successful market entry, companies must focus on product affordability, user comfort, and telemedicine integration. Expanding into Asia-Pacific with scalable, portable, and AI-enabled diagnostic tools offers a high-potential growth avenue, given the rising healthcare penetration. Strategic partnerships with local providers and government awareness programs will be key to unlocking untapped markets and gaining competitive advantage.

High-integrity carbon removal credits will be used to support buyer’s decarbonization and to mitigate corporate travel emissions

New York, United States, July 21, 2025 (GLOBE NEWSWIRE) -- Graphjet Technology (“Graphjet” or “the Company”) (Nasdaq:GTI), a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, is proud to announce that the Company is expecting for new equipment and machineries to arrive in Malaysia by the end of the week.